The pharmaceutical sector remains one of the more popular sector among investors and this morning, it is likely that the Claritas Pharmaceuticals Inc (OTCMKTS:KALTF) stock that is expected to come into focus among many. The stock continued on its good run yesterday and ended the day with gains of 8%.
Trading Data
On Tuesday, KALTF stock surged 7.65% to $0.1927 with more than 100 shares, compared to its average volume of 20k shares. The stock has moved within a range of $0.1927 – 0.1927 after opening trade at $0.1927.
Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries
That rally took the gains made by the stock over the course of the past week to as much as 48%. In this context, it is necessary to note that yesterday the Claritas Pharmaceuticals stock came into focus after it announced its plans with regards to the development of its nitric oxide releasing product R-107 which can be used for a range of clinical indications.
The President and Chief Executive Officer of the company Robert Farrell spoke about the matter as well. He stated that the company is now in a position at which it can start accelerating the development of the R 107 product and treat a wide range of conditions. It goes without saying that such a statement can often prove to be a major bullish trigger for the company’s stock and that is what happened with the Claritas Pharmaceuticals stock.
Technical Data
KALTF stock is trading above the 20-Day and 50-Day Moving averages of $0.15 and $0.15 respectively. However, the stock is trading below the 200-Day moving average of $0.38. The stock is up 19% in the past month.
